Clinical Trials on Gastroesophageal Junction Carcinoma

Total 26585 results

Cancer Institute and Hospital, Chinese Academy...

Completed

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
AIO-Studien-gGmbH
Roche Pharma AG

Completed

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)

Adenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the Stomach

Germany
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia
VA Office of Research and Development
VA Palo Alto Health Care System; VA Puget Sound Health Care System; Michael E... and other collaborators

Not yet recruiting

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Carcinoma

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
LianBio LLC

Recruiting

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (FGFR)

Gastric Cancer | Solid Tumor | Gastroesophageal Junction Adenocarcinoma

China
University of Oxford

Completed

Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United Kingdom
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)

Gastric Cancer | Gastroesophageal Junction Cancer

Japan, Korea, Republic of, Taiwan, Singapore, United States
Hellenic Cooperative Oncology Group
Boehringer Ingelheim

Completed

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)

Gastric Cancer | Gastroesophageal Junction Cancer

Greece
Auxilio Mutuo Cancer Center

Recruiting

Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Colorectal Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Low Grade Lymphoma

Puerto Rico
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
Toray Industries, Inc

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Japan
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
European Organisation for Research and Treatment...

Terminated

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

Belgium, Portugal, Germany
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (MATEO)

Esophageal Neoplasms | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Gastric Neoplasm | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Germany
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan
Hoffmann-La Roche

Completed

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Gastric Cancer, Gastroesophageal Junction Cancer

France
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
UNICANCER
Servier

Recruiting

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer (LOGICAN)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Esophagus Adenocarcinoma

France
ALX Oncology Inc.
Eli Lilly and Company

Recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Spain, France, Korea, Republic of, Taiwan, United Kingdom, Japan, Singapore, Belgium, Czechia, Italy
Imugene Limited

Active, not recruiting

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Cancer of Stomach | Stomach Adenocarcinoma

Taiwan, Australia
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Federation Francophone de Cancerologie Digestive

Completed

Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

France
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
University Hospital Heidelberg
German Cancer Research Center; University Hospital Dresden

Active, not recruiting

OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma (OPPOSITE)

Esophageal Neoplasms | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Gastric Neoplasm

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Arbele Pty Ltd

Recruiting

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Gastric Cancer | Pancreatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Gastrointestinal Cancer | Liver Cancer | Colorectal Adenocarcinoma | Gastroesophageal Junction

Hong Kong, Australia
MedPacto, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Metastatic Colorectal Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Gastric Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Stomach | Stage IV Esophageal Adenocarcinoma AJCC v7 | Stage IV Esophageal Squamous Cell Carcinoma AJCC v7

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
BeiGene

Active, not recruiting

Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Cancer

China, Taiwan, Korea, Republic of
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

Peritoneal Carcinomatosis | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Shanghai Henlius Biotech

Recruiting

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
Federation Francophone de Cancerologie Digestive
Eli Lilly and Company

Active, not recruiting

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE)

Stomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Neoplasm

France
Yonsei University

Completed

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of
Kuhnil Pharmaceutical Co., Ltd.
Daiichi Sankyo Co., Ltd.

Terminated

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Taiwan, Japan, Korea, Republic of
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Hanmi Pharmaceutical Company Limited

Completed

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

Non-erosive Gastroesphageal Reflux Disease

Korea, Republic of
Yonsei University

Completed

Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease

Non-erosive Gatroesophageal Reflux Disease

Korea, Republic of
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Advanced Cancer | Hepatocellular Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Second Affiliated Hospital, School of Medicine,...
TCRx Therapeutics Co.Ltd

Not yet recruiting

TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy

Gastric Cancer | Gastroesophageal-junction Cancer
Precirix

Terminated

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment

United States, Canada
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan

Clinical Trials on Gastroesophageal Junction Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations